CareDx Inc. (CDNA)
NASDAQ: CDNAHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CDNA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.68B
- P/E (TTM)
- 29.54
- Forward P/E
- 44.75
- EPS (TTM)
- $2.37
- Dividend yield
- None
- 52-week range
- 15.56 – 90.87
- Day range
- 69.26 – 72.81
- Volume / Avg
- 781.92K / 1.30M
- Beta
- —
- Shares outstanding
- 52.54M
52-week range
CDNA stock today
Shares of CareDx (CDNA) finished lower on Nov 20 at $70.00, a drop of 2.67% or $1.92 per share, versus the S&P 500's 3.70% decline. At this level, CDNA sits in the middle of its 52-week range of $15.56 to $90.87: 23.0% below the high, set on Oct 30, 2026 and 349.9% above the low. CDNA is up 271.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 307.5%.
At 29.5x trailing earnings, CareDx trades above the peer-group median of 20.5x. Its forward P/E of 44.7x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About CareDx
Company profileCareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. John Walter Hanna Jr.
- Headquarters
- Brisbane, CA
- Employees
- 761
- IPO year
- 2014
- Website
- caredx.com
Financial highlights
Full financialsIn fiscal 2025, CareDx generated $379.8 million in revenue, up 13.8% from fiscal 2024, its 2nd consecutive year of revenue growth. CareDx reported a net loss of $21.4 million, compared with net income of $52.5 million a year earlier. Operating margin was -8.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $379.81M | $333.79M | $280.32M | $321.79M | $296.40M |
| Growth | +13.79% | +19.07% | -12.89% | +8.57% | +54.22% |
| Net income | $-21.35M | $52.55M | $-190.28M | $-76.61M | $-30.66M |
| EPS (diluted) | $-0.40 | $0.93 | $-3.54 | $-1.44 | $-0.59 |
Analyst forecast
ForecastConsensus (8 analysts)
buy
Avg. price target
$94.43+34.90%
- Strong buy 1
- Buy 5
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 29, 2026
- EPS actual vs est.
- $0.35 vs $0.07
- Surprise
- +400.00%
CDNA news
All CDNA news- CareDx is a new Overweight at Piper Sandler on transplant testing opportunitySeeking Alpha
- Piper Sandler Initiates Coverage of CareDx at OverweightNasdaqCDNA, BIO.B
- CareDx Consensus Price Target Increased by 40.49% to $87.89NasdaqCDNA, BF.A
- Why CareDx Stock Soared TodayNasdaq
- Healthcare Stocks Trade Higher: CDNA Gains 20%, REGN Adds 12%, PROF Climbs 10%, AZN Advances 7%NasdaqAZN, CDNA, PROF, REGN
- CareDx raises 2026 revenue outlook to $520M-$530M as it plans AlloHeme launch in Q1 2027Seeking Alpha
- CareDx Q3 Revenue Jumps 39%; Raises FY26 Revenue, EBITDA Guidance; Stock UpNasdaqCDNA, BRK.A
- CareDx, Inc. Reports Third Quarter 2026 Revenue Growth of 39% to $139 MillionNasdaq
CareDx peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ACHCAcadia Healthcare Company Inc. | 34.60 | +0.38% | $3.22B | vs CDNA |
| BLLNBillionToOne Inc. Class A | 89.92 | -0.31% | $4.30B | vs CDNA |
| GRALGRAIL Inc. | 99.25 | -5.33% | $4.46B | vs CDNA |
| CELCCelcuity Inc. | 53.35 | -5.26% | $2.61B | vs CDNA |
| CAICaris Life Sciences Inc. | 17.58 | -5.18% | $5.04B | vs CDNA |
| CONConcentra Group Holdings Parent Inc. | 41.84 | +0.94% | $5.26B | vs CDNA |
| VCYTVeracyte Inc. | 25.13 | +0.36% | $2.03B | vs CDNA |
| CLOVClover Health Investments Corp. Class A | 3.73 | -1.06% | $2.00B | vs CDNA |
Indexes, lists and sector
CareDx stock FAQ
What is CareDx's stock price today?
CDNA last traded at $70.00 as of Nov 20, 4:00 PM EST, down 2.67% on the day. Prices are delayed at least 15 minutes.
What is CDNA's P/E ratio?
CDNA trades at a trailing P/E ratio of 29.54 and a forward P/E of 44.75, compared with a median of 20.5 for its closest peers.
Who is CareDx's CEO?
Mr. John Walter Hanna Jr. is the chief executive officer of CareDx Inc., which has about 761 employees.
What is the CDNA 52-week high?
The 52-week high for CDNA is $90.87 and the 52-week low is $15.56. The stock is currently 23.0% below its high.